Indivior (NASDAQ:INDV) Releases Earnings Results, Meets Expectations

Indivior (NASDAQ:INDV) released its quarterly earnings results on Thursday. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32, Zacks reports. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Indivior updated its FY 2025 guidance to EPS.

Indivior Price Performance

Shares of NASDAQ:INDV traded down $1.74 during trading on Thursday, reaching $9.17. 1,219,757 shares of the company’s stock traded hands, compared to its average volume of 1,136,186. The company has a 50 day moving average of $11.56 and a 200-day moving average of $10.89. Indivior has a 12 month low of $7.33 and a 12 month high of $23.22. The stock has a market capitalization of $1.26 billion, a P/E ratio of -231.42 and a beta of 0.73.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 target price (up from $15.00) on shares of Indivior in a research report on Friday, October 25th. Rodman & Renshaw began coverage on Indivior in a research note on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.